Market Summary
USD188.35+0.35
Delayed0.19%
IQV Alerts
IQV Stock Price
IQV RSI Chart
IQV Valuation
IQV Price/Sales (Trailing)
IQV Profitability
IQV Fundamentals
IQV Revenue
IQV Earnings
Price Action
52 Week Range
165.75254.94
(Low)(High)
Last 7 days
-4.1%
Last 30 days
-10.7%
Last 90 days
-7.6%
Trailing 12 Months
-16.2%
IQV Financial Health
IQV Investor Care
Peers (Alternatives to Iqvia Holdings)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
A | 38.9B | 6.8B | -7.12% | -2.94% | 31.04 | 5.68 | 8.37% | 3.64% |
IQV | 35.0B | 14.4B | -10.73% | -16.15% | 32.06 | 2.43 | 3.86% | 12.94% |
ILMN | 34.8B | 4.6B | 9.07% | -35.87% | -7.89 | 7.58 | 1.28% | -677.95% |
CRL | 9.9B | 4.0B | -11.55% | -31.05% | 20.3 | 2.48 | 12.31% | 24.36% |
| MID-CAP | ||||||||
MEDP | 5.7B | 1.5B | -7.14% | 13.35% | 23.05 | 3.87 | 27.80% | 34.93% |
SYNH | 3.6B | 5.4B | -7.30% | -56.29% | 13.33 | 0.66 | 3.46% | 13.48% |
ARWR | 2.6B | 278.3M | -26.06% | -48.44% | -16.69 | 9.26 | 92.72% | 15.56% |
NEO | 2.1B | 509.7M | 26.37% | -5.44% | -14.51 | 4.11 | 5.24% | -1628.17% |
| SMALL-CAP | ||||||||
AVXL | 680.4M | - | -13.75% | -31.50% | -13.59 | 291.16 | -34.21% | -22.31% |
CDXS | 255.3M | 138.6M | -29.45% | -81.04% | -7.6 | 1.84 | 32.30% | -57.86% |
PGEN | 199.8M | 80.7M | -24.99% | -55.14% | 7.06 | 4.15 | 13.30% | 130.72% |
SRNE | 143.9M | 60.3M | -71.28% | -88.95% | -0.29 | 2.39 | 17.51% | -38.93% |
PSNL | 121.4M | 65.0M | -18.24% | -68.45% | -1.07 | 1.87 | -23.92% | -73.73% |
Financials for Iqvia Holdings
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 0.7% | 14,410 | 14,307 | 14,136 | 14,033 | 13,874 |
| Gross Profit | 3.7% | 3,208 | 3,095 | 2,988 | - | - |
| S&GA Expenses | 2.0% | 2,071 | 2,030 | 2,011 | 2,010 | 1,964 |
| EBITDA | 1.1% | 2,909 | 2,877 | 2,862 | 2,829 | - |
| EBITDA Margin | 0.4% | 0.20* | 0.20* | 0.20* | 0.20* | - |
| Earnings Before Taxes | -6.9% | 1,363 | 1,464 | 1,377 | 1,271 | 1,128 |
| EBT Margin | -7.6% | 0.09* | 0.10* | 0.10* | 0.09* | - |
| Interest Expenses | 10.1% | 416 | 378 | 362 | 362 | 375 |
| Net Income | -7.7% | 1,091 | 1,182 | 1,160 | 1,079 | 966 |
| Net Income Margin | -8.4% | 0.08* | 0.08* | 0.08* | 0.08* | - |
| Free Cahsflow | -5.5% | 2,260 | 2,392 | 2,373 | 2,583 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 4.6% | 25,337 | 24,223 | 24,413 | 24,969 | 24,689 |
| Current Assets | 4.8% | 4,981 | 4,752 | 4,911 | 4,772 | 4,763 |
| Cash Equivalents | -4.6% | 1,216 | 1,274 | 1,428 | 1,387 | 1,366 |
| Net PPE | 4.9% | 532 | 507 | 529 | 531 | 497 |
| Goodwill | 5.6% | 13,921 | 13,177 | 13,104 | 13,532 | 13,301 |
| Liabilities | 3.7% | 19,572 | 18,876 | 19,061 | 19,050 | 18,647 |
| Current Liabilities | 6.2% | 5,578 | 5,253 | 5,104 | 5,157 | 5,241 |
| LT Debt, Current | 0.7% | 152 | 151 | 152 | 90.00 | 91.00 |
| LT Debt, Non Current | 2.9% | 12,595 | 12,243 | 12,615 | 12,547 | 12,034 |
| Shareholder's Equity | 7.8% | 5,765 | 5,347 | 5,352 | 5,919 | 6,042 |
| Retained Earnings | 7.3% | 3,334 | 3,107 | 2,824 | 2,568 | 2,243 |
| Accumulated Depreciation | - | 765 | - | - | - | - |
| Shares Outstanding | -0.1% | 186 | 186 | 187 | 189 | 191 |
| Minority Interest | - | - | - | - | - | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -5.5% | 2,260 | 2,392 | 2,373 | 2,583 | 2,942 |
| Share Based Compensation | 9.0% | 194 | 178 | 165 | 168 | 170 |
| Cashflow From Investing | 7.8% | -2,006 | -2,176 | -2,554 | -2,540 | -2,103 |
| Cashflow From Financing | -20.1% | -329 | -274 | -89.00 | -923 | -1,235 |
| Buy Backs | -10.6% | 1,168 | 1,307 | 1,192 | 747 | 406 |
Risks for IQV
What is the probability of a big loss on IQV?
41.1%
Probability that Iqvia Holdings stock will be more than 20% underwater in next one year
35%
Probability that Iqvia Holdings stock will be more than 30% underwater in next one year.
18.5%
Probability that Iqvia Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does IQV drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Iqvia Holdings was unfortunately bought at previous high price.
Drawdowns
Returns for IQV
Cumulative Returns on IQV
16.6%
7-Year Cumulative Returns
13.6%
5-Year Cumulative Returns
24.8%
3-Year Cumulative Returns
What are the long-term rolling returns for IQV?
FIve years rolling returns for Iqvia Holdings.
Annualized Returns
Which funds bought or sold IQV recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 24.26 | 283,316 | 985,316 | 0.03% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 3.39 | 3,371,390 | 23,262,400 | 0.03% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | reduced | -2.32 | 1,198,050 | 12,614,100 | 1.97% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 397 | 16,441,000 | 19,990,000 | 0.10% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | unchanged | - | 151,003 | 1,299,000 | 0.08% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | new | - | 13,933 | 13,933 | 0.01% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 63,819,400 | 63,819,400 | 0.79% |
2023-02-28 | Voya Investment Management LLC | reduced | -0.45 | 26,933,400 | 240,646,000 | 0.34% |
2023-02-27 | ST GERMAIN D J CO INC | new | - | 23,562 | 23,562 | 0.01% |
2023-02-24 | SRS Capital Advisors, Inc. | sold off | -100 | -4,000 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
IQV Alerts
Iqvia Holdings News
Schedule 13G FIlings of Iqvia Holdings
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 11.55% | 21,447,600 | SC 13G/A | |
| Feb 07, 2023 | blackrock inc. | 8.5% | 15,763,249 | SC 13G/A | |
| Feb 07, 2022 | blackrock inc. | 7.9% | 15,139,662 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.93% | 20,954,687 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 7.7% | 14,826,277 | SC 13G/A | |
| Feb 10, 2020 | vanguard group inc | 10.03% | 19,475,899 | SC 13G/A | |
| Feb 10, 2020 | vanguard group inc | 9.97% | 19,346,266 | SC 13G/A | |
| Feb 05, 2020 | blackrock inc. | 7.6% | 14,685,767 | SC 13G/A | |
| Oct 10, 2019 | vanguard group inc | 10.24% | 20,064,602 | SC 13G/A |
IQV Fair Value
Iqvia Holdings fair value in different scenarios
The table shows the Fair Value estimates for Iqvia Holdings for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 78.94 -58.09% | 100.31 -46.74% | 138.31 -26.57% | 183.07 -2.80% | 226.36 20.18% |
| Current Inflation | 72.25 -61.64% | 90.39 -52.01% | 122.07 -35.19% | 159.28 -15.43% | 195.23 3.65% |
| Very High Inflation | 64.05 -65.99% | 78.47 -58.34% | 103.05 -45.29% | 131.87 -29.99% | 159.71 -15.21% |
Historical Iqvia Holdings Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Iqvia Holdings
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Feb 27, 2023 | DEF 14A | DEF 14A | |
| Feb 27, 2023 | DEFA14A | DEFA14A | |
| Feb 17, 2023 | 4 | Insider Trading | |
| Feb 17, 2023 | PRE 14A | PRE 14A | |
| Feb 15, 2023 | 10-K | Annual Report | |
| Feb 15, 2023 | 4 | Insider Trading | |
| Feb 15, 2023 | 4 | Insider Trading | |
| Feb 15, 2023 | 4 | Insider Trading | |
| Feb 15, 2023 | 4 | Insider Trading | |
| Feb 15, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for IQV
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-02-16 | Knightly Kevin C | sold | -1,003,070 | 225 | -4,446 | see remarks |
2023-02-14 | Sherbet Eric | sold | -230,000 | 230 | -1,000 | see remarks |
2023-02-11 | Cherofsky Keriann | sold (taxes) | -12,033 | 222 | -54.00 | see remarks |
2023-02-11 | Panagos Constantinos | sold (taxes) | -307,965 | 222 | -1,382 | see remarks |
2023-02-10 | Bruehlman Ronald E | sold (taxes) | -136,824 | 222 | -614 | see remarks |
2023-02-10 | BOUSBIB ARI | sold (taxes) | -779,049 | 222 | -3,496 | see remarks |
2023-02-10 | Cherofsky Keriann | sold (taxes) | -3,342 | 222 | -15.00 | see remarks |
2023-02-10 | Knightly Kevin C | sold (taxes) | -67,520 | 222 | -303 | see remarks |
2023-02-10 | Panagos Constantinos | sold (taxes) | -64,400 | 222 | -289 | see remarks |
2023-02-10 | Sherbet Eric | sold (taxes) | -72,645 | 222 | -326 | see remarks |
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
IQV Income Statement
2022-12-31CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Income Statement [Abstract] | |||
| Revenues | $ 14,410 | $ 13,874 | $ 11,359 |
| Cost of revenues, exclusive of depreciation and amortization | 9,382 | 9,233 | 7,500 |
| Selling, general and administrative expenses | 2,071 | 1,964 | 1,789 |
| Depreciation and amortization | 1,130 | 1,264 | 1,287 |
| Restructuring costs | 28 | 20 | 52 |
| Income from operations | 1,799 | 1,393 | 731 |
| Interest income | (13) | (6) | (6) |
| Interest expense | 416 | 375 | 416 |
| Loss on extinguishment of debt | 0 | 26 | 13 |
| Other expense (income), net | 33 | (130) | (65) |
| Income before income taxes and equity in (losses) earnings of unconsolidated affiliates | 1,363 | 1,128 | 373 |
| Income tax expense | 260 | 163 | 72 |
| Income before equity in (losses) earnings of unconsolidated affiliates | 1,103 | 965 | 301 |
| Equity in (losses) earnings of unconsolidated affiliates | (12) | 6 | 7 |
| Net income | 1,091 | 971 | 308 |
| Net income attributable to non-controlling interests | 0 | (5) | (29) |
| Net income attributable to IQVIA Holdings Inc. | $ 1,091 | $ 966 | $ 279 |
| Earnings per share attributable to common stockholders: | |||
| Basic (in dollars per share) | $ 5.82 | $ 5.05 | $ 1.46 |
| Diluted (in dollars per share) | $ 5.72 | $ 4.95 | $ 1.43 |
| Weighted average common shares outstanding: | |||
| Basic (in shares) | 187.6 | 191.4 | 191.3 |
| Diluted (in shares) | 190.6 | 195.0 | 195.0 |
IQV Balance Sheet
2022-12-31CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| ASSETS | ||
| Cash and cash equivalents | $ 1,216 | $ 1,366 |
| Trade accounts receivable and unbilled services, net | 2,917 | 2,551 |
| Prepaid expenses | 151 | 156 |
| Income taxes receivable | 43 | 58 |
| Investments in debt, equity and other securities | 93 | 111 |
| Other current assets and receivables | 561 | 521 |
| Total current assets | 4,981 | 4,763 |
| Property and equipment, net | 532 | 497 |
| Operating lease right-of-use assets | 331 | 406 |
| Investments in debt, equity and other securities | 68 | 76 |
| Investments in unconsolidated affiliates | 94 | 88 |
| Goodwill | 13,921 | 13,301 |
| Other identifiable intangibles, net | 4,820 | 4,943 |
| Deferred income taxes | 118 | 124 |
| Deposits and other assets, net | 472 | 491 |
| Total assets | 25,337 | 24,689 |
| Current liabilities: | ||
| Accounts payable and accrued expenses | 3,316 | 2,981 |
| Unearned income | 1,797 | 1,825 |
| Income taxes payable | 161 | 137 |
| Current portion of long-term debt | 152 | 91 |
| Other current liabilities | 152 | 207 |
| Total current liabilities | 5,578 | 5,241 |
| Long-term debt, less current portion | 12,595 | 12,034 |
| Deferred income taxes | 464 | 410 |
| Operating lease liabilities | 264 | 313 |
| Other liabilities | 671 | 649 |
| Total liabilities | 19,572 | 18,647 |
| Commitments and contingencies (Note 1 and 12) | ||
| Stockholders’ equity: | ||
| Common stock and additional paid-in capital, 400.0 shares authorized as of December 31, 2022 and 2021, $0.01 par value, 256.4 shares issued and 185.7 shares outstanding as of December 31, 2022; 255.8 shares issued and 190.6 shares outstanding as of December 31, 2021 | 10,898 | 10,777 |
| Retained earnings | 3,334 | 2,243 |
| Treasury stock, at cost, 70.7 and 65.2 shares as of December 31, 2022 and 2021, respectively | (7,740) | (6,572) |
| Accumulated other comprehensive loss | (727) | (406) |
| Total stockholders’ equity | 5,765 | 6,042 |
| Total liabilities and stockholders’ equity | $ 25,337 | $ 24,689 |